BioOhio is going to Washington.
Officials from the state’s bioscience company development organization will meet with members of Congress today and tomorrow to discuss issues critical to the continued growth of bioscience business and research in Ohio, said organization spokesman Matt Schutte.
BioOhio is scheduled to meet with 11 Ohio congresspeople or staff members, as well as with Ohio Gov. Ted Strickland’s staff in Washington and with staff of AdvaMed, the medical technology trade association.
The Impact Brands: Empowering Wellness Through Natural and Holistic Solutions
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
“As Ohio gains national bioscience prominence, and as our industry grows and becomes a larger part of Ohio’s economy, BioOhio will continue to address issues of common interest but also address areas that are of specific interest to Ohio,” said BioOhio President & CEO Tony Dennis, in a written statement.
“Ohio’s bioscience industry is very well-positioned to benefit from the federal stimulus, which can help us maintain our growth momentum and ensure that bioscience is part of the long-term solution for creating a robust and resurgent Ohio economy,” said Dennis, one of the BioOhio delegation to Washington.
BioOhio defines bioscience as 1) commercial bioscience companies, institutions and organizations; 2) hospitals and health care providers; and 3) medical colleges.
BioOhio believes that bioscience in Ohio has an economic impact of $148.2 billion, which is equal to 15.7 percent of the state’s total economic output. Bioscience also directly and indirectly generates 1.4 million jobs in Ohio, the organization said.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
As of Dec. 31, 1,141 bioscience entities operated in the state, according to its Ohio Bioscience Growth Report 2007-08. These entities do research, development and marketing of pharmaceuticals, diagnostics, bioinformatics, medical devices, medical equipment, biotechnology products and health-related products.
More stories that deserve a read:
Senate lacks votes to pass stimulus (Washington Post)
M&A activity in health care is way down (BNET Healthcare)
FDA panel gives Prasugrel thumbs up (WSJ Health Blog)
As nominee trips, health care drive suffers a setback (New York Times)
Rogue stem cell clinics damage global health (HealthLeaders Media)
